Gorman criticized American pharmaceutical manufacturers for keeping the prices of new drugs (e.g., anti-psychotic tranquilizers) unaffordably high for some patients, for spending far too much on advertising new drugs, for flooding the market with "new" drugs that were minor variations on older drugs, for inflating the amount the industry spent on original research, and for behaving as though drug patents were more precious than human lives. The hearings of the Senate Antitrust and Monopoly Subcommittee, chaired by Sen. Estes Kefauver, extended over several years and included several other large industries.
Copyright:
The National Library of Medicine believes this item to be in the public domain. (More information)